Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Vir Biotechnology, Inc. (VIR)

Nasdaq Health Care Biotechnology S&P SmallCap 600
$12.21
+1.19 (+10.80%)
Close of Nov 06, 2026 · end-of-day data
Source: Vir Biotechnology, Inc.'s 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 05, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$2.71M$10.67M$8.09M$76.37M$1.10B$1.62B$86.18M$74.20M$68.56M
Cost of revenue——$0$0$65.86M$146.32M$2.77M$845.00K$26.00K
Gross profit——$8.09M$76.37M$1.03B$1.47B$83.42M$73.36M$68.53M
Research & development$62.51M$100.23M$148.47M$302.41M$448.01M$474.65M$579.72M$506.50M$455.97M
Selling, general & admin——$37.60M$70.94M$160.79M$161.76M$174.44M$119.03M$92.07M
Operating income-$81.50M-$118.69M-$177.98M-$296.98M$420.75M$833.07M-$684.30M-$587.16M-$479.33M
Pre-tax income-$80.78M-$116.36M-$174.53M-$298.61M$549.80M$754.28M-$628.19M-$523.11M-$437.77M
Income tax-$10.92M-$480.00K$154.00K$54.00K$21.22M$238.44M-$13.08M-$1.15M$217.00K
Net income-$69.85M-$115.88M-$174.68M-$298.67M$528.58M$515.84M-$615.06M-$521.96M-$437.99M
EBITDA-$81.24M-$117.07M-$174.69M-$292.58M$426.03M$839.85M-$664.85M-$572.61M-$467.65M
EPS (basic)$-32.45$-15.12$-5.76$-2.51$4.07$3.89$-4.59$-3.83$-3.16
EPS (diluted)$-32.45$-15.12$-5.76$-2.51$3.96$3.83$-4.59$-3.83$-3.16
Diluted shares2.15M7.67M30.35M119.16M133.44M134.81M134.13M136.25M138.52M
Gross margin——100.0%100.0%94.0%90.9%96.8%98.9%100.0%
Operating margin-3009.5%-1112.6%-2199.7%-388.9%38.4%51.6%-794.0%-791.3%-699.2%
Net margin-2579.5%-1086.3%-2159.0%-391.1%48.3%31.9%-713.7%-703.4%-638.9%

Balance sheet

fiscal years · USD
Fiscal yearFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$187.92M$47.60M$109.33M$436.57M$347.81M$848.63M$241.58M$222.95M$232.19M
Short-term investments—$50.84M$274.10M$300.29M$217.18M$1.52B$1.27B$678.05M$228.75M
Receivables———$0$773.08M$0———
Total current assets—$117.78M$403.00M$772.37M$1.56B$2.52B$1.59B$1.04B$514.08M
Goodwill—$16.94M$16.94M$16.94M$16.94M$16.94M$16.94M$16.94M$16.94M
Total assets—$191.60M$512.07M$918.76M$1.95B$2.80B$1.92B$1.40B$1.00B
Total current liabilities—$39.91M$59.21M$99.06M$341.24M$511.03M$175.41M$119.66M$92.81M
Total liabilities—$61.64M$88.13M$201.91M$522.42M$724.12M$328.82M$248.43M$237.55M
Shareholders' equity-$68.92M-$179.18M$423.94M$716.85M$1.43B$2.08B$1.59B$1.15B$765.28M

Cash flow

fiscal years · USD
Fiscal yearFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$66.38M-$94.10M-$129.63M-$190.94M-$47.59M$1.66B-$778.78M-$446.35M-$391.78M
Capital expenditures$2.74M$8.19M$8.94M$6.55M$21.82M$68.01M$21.57M$7.30M$4.83M
Free cash flow-$69.12M-$102.29M-$138.57M-$197.49M-$69.41M$1.60B-$800.36M-$453.65M-$396.61M
Investing cash flow-$29.99M-$60.44M-$256.16M-$9.86M-$140.81M-$1.19B$164.63M$499.37M$310.37M
Financing cash flow$271.18M$24.98M$449.24M$529.47M$100.33M$34.76M$7.48M$4.39M$3.79M
Stock-based compensation$4.78M$5.05M$8.72M$27.60M$83.78M$102.08M$111.32M$78.46M$49.07M
Depreciation & amortization$255.00K$1.62M$3.29M$4.40M$5.28M$6.78M$19.45M$14.56M$11.68M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.